Century Therapeutics, Inc. Common Stock

IPSCNASDAQ • USD
1.64 USD
↘ 0.01 (0.61%)AT CLOSE (03:59 PM EST)
1.64
↘ 0.01 (0.31%)
POST MARKET (AS OF 04:14 PM EST)
Post Market
AS OF 04:14 PM EST
1.64
↘ 0.01 (0.31%)
🔴Market: CLOSED

IPSC is currently priced at $1.63. The technical outlook is "Neutral" and the fundamental picture shows "Sell". Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.

Technical & fundamental data as of Nov 16, 2026.

Open?$1.65
High?$1.71
Low?$1.57
Prev. Close?$1.65
Volume?910.0K
Avg. Volume?994.1K
VWAP?$1.62
Rel. Volume?0.92x
Bid / Ask
Bid?$1.57 × 100
Ask?$1.64 × 100
Spread?$0.07
Midpoint?$1.61
Valuation & Ratios
Market Cap?299.6M
Shares Out?181.6M
Float?124.7M
Float %?69.1%
P/E Ratio?N/A
P/B Ratio?1.43
EPS?-$0.54
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
Employees
78
Market Cap
299.6M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed
2021-06-18
Address
25 N 38TH STREET, 12TH FLOOR
PHILADELPHIA, PA
Phone: 215-981-4000
Technical OutlookNeutral
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+1/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
65
Short Sent.?
5
Piotroski F-Score?0/9Weak
Altman Z-Score?-2.07Distress
Confidence?54%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?25.69%Squeeze Risk
Short Interest?32.0M
Days to Cover?31.0
Free Float124.7M
Avg Daily Volume1.0M
Settlement Date2026-10-30
Financial Health
Current Ratio?8.74Strong
Quick Ratio?8.74Strong
Cash Ratio?3.21Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
89
1.43CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-3.1CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-47.1%WEAK▾
ROA?
S&P
3
-37.6%WEAK▾
Cash Flow & Enterprise
FCF?$-85075000
Enterprise Value?$254.6M
Fundamentals ratios updated end of day